Miguel Arquez
Miguel Arquez has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
L. Torres
Hosp Univ St Joan Reus, Reus, Reunion, Spain
4 shared publicationsM. Arenas Prat
Hosp Univ St Joan Reus, Radiat Oncol, Reus, Spain
4 shared publicationsS. Sabater
Hosp Univ St Joan Reus, Radiat Oncol, Reus, Spain
4 shared publicationsM. Arenas
Hosp Univ St Joan de Reus, Dept Radiat Oncol, Reus, Spain
3 shared publicationsM. Bonet
Hosp Univ St Joan Reus, Radiat Oncol, Reus, Spain
3 shared publicationsAdel Saleh
2 shared publications
Latest Publications
- 1 March 2020
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 25 (2) , 250-254
Low-Dose radiation therapy for benign pathologies
Radiotherapy (RT) has always been a mainstay for malignant tumors therapy, but it is also used for benign pathology. The application of low or intermediate doses of RT has been widely studied. This topic was presented and discussed in the last XX GOCO (Grup Oncològic Català-Occità) meeting. The aim of this article is to review the indications of low dose irradiation (LD-RT), total dose and different fractionations, the public to whom it can be directed, and to offer an analysis about secondary effects. We believe it can be useful not only for radiation oncologists, but for other physicians to consider this option for future patients.
- 1 March 2020
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 25 (2) , 250-254
Low-Dose radiation therapy for benign pathologies
Radiotherapy (RT) has always been a mainstay for malignant tumors therapy, but it is also used for benign pathology. The application of low or intermediate doses of RT has been widely studied. This topic was presented and discussed in the last XX GOCO (Grup Oncològic Català-Occità) meeting. The aim of this article is to review the indications of low dose irradiation (LD-RT), total dose and different fractionations, the public to whom it can be directed, and to offer an analysis about secondary effects. We believe it can be useful not only for radiation oncologists, but for other physicians to consider this option for future patients.
- Top Cited Papers
- 1 January 2020
- Published by Elsevier in Expert Systems with Applications
- Vol. 139
Breast tumor segmentation and shape classification in mammograms using generative adversarial and convolutional neural network
- 1 January 2020
- Published by Elsevier in Expert Systems with Applications
- Vol. 139
Top Cited PapersBreast tumor segmentation and shape classification in mammograms using generative adversarial and convolutional neural network
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E666-E667
Radiotherapy Treatment Effects on the Energy Metabolism in LUNG, Head and Neck Cancer Patients
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E666-E667
Radiotherapy Treatment Effects on the Energy Metabolism in LUNG, Head and Neck Cancer Patients
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E278-E279
Influence of Statins on Survival Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Inhibitors
- 1 September 2019
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 105 (1) , E278-E279
Influence of Statins on Survival Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Inhibitors
- Open Access
- 1 April 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 133, S599-S600
PO-1079 Metabolic changes with the administration of radiotherapy in lung, head and neck cancer patients
- 1 April 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 133, S599-S600
Open AccessPO-1079 Metabolic changes with the administration of radiotherapy in lung, head and neck cancer patients
- 26 September 2018
- Published by Springer Nature
- p. 833-840
Conditional Generative Adversarial and Convolutional Networks for X-ray Breast Mass Segmentation and Shape Classification
- 26 September 2018
- Published by Springer Nature
- p. 833-840
Conditional Generative Adversarial and Convolutional Networks for X-ray Breast Mass Segmentation and Shape Classification
- Open Access
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S735
EP-1345: Prevalence of asymptomatic pericardial effusion in breast cancer patients referred for RT
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S735
Open AccessEP-1345: Prevalence of asymptomatic pericardial effusion in breast cancer patients referred for RT
- Open Access
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S1271
EP-2303: Should radiotherapy be avoided after neoadjuvant chemotherapy in complete response breast cancer?
- 1 April 2018
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 127, S1271
Open AccessEP-2303: Should radiotherapy be avoided after neoadjuvant chemotherapy in complete response breast cancer?
- 1 May 2017
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 22 (3) , 251-257
Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy
Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT). CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006. CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed. Median CCP score was 0.9 (-0-1 - 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%. BF and DSM were observed in 21% and 9%. Ki-67 ≥ 15% predicted BF (p = 0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76-71% (p = 0.83), 83-73% (p = 0.86), 89-85% (p = 0.84), and 94-78% (p = 0.66). On univariate, high Ki-67 was correlated with BF (p = 0.013), OS (p = 0.023), DM (p = 0.007), and DSM (p = 0.01). On Cox MVA, high Ki-67 had a BF trend (p = 0.063). High CCP score was not correlated with DSM. High Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.
- 1 May 2017
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 22 (3) , 251-257
Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy
Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT). CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006. CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed. Median CCP score was 0.9 (-0-1 - 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%. BF and DSM were observed in 21% and 9%. Ki-67 ≥ 15% predicted BF (p = 0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76-71% (p = 0.83), 83-73% (p = 0.86), 89-85% (p = 0.84), and 94-78% (p = 0.66). On univariate, high Ki-67 was correlated with BF (p = 0.013), OS (p = 0.023), DM (p = 0.007), and DSM (p = 0.01). On Cox MVA, high Ki-67 had a BF trend (p = 0.063). High CCP score was not correlated with DSM. High Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.
- Open Access
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 3 (3) , 270-276
Individualized 3D scanning and printing for non-melanoma skin cancer brachytherapy: a financial study for its integration into clinical workflow
Purpose: Skin cancer is the most common tumor in the population. There are different therapeutic modalities. Brachytherapy is one of the techniques used, in which it is necessary to build customized moulds for some patients. Currently, these moulds are made by hand using rudimentary...
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 3 (3) , 270-276
Open AccessIndividualized 3D scanning and printing for non-melanoma skin cancer brachytherapy: a financial study for its integration into clinical workflow
Purpose: Skin cancer is the most common tumor in the population. There are different therapeutic modalities. Brachytherapy is one of the techniques used, in which it is necessary to build customized moulds for some patients. Currently, these moulds are made by hand using rudimentary...